{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:01:28Z","timestamp":1790226088747,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Reiss Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schizophr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Clozapine is the most effective and only approved drug for treatment-resistant schizophrenia (TRS). Studies based on data up to 2014 concluded that it is underutilized in most industrialized countries, including Germany. Since 2019, national guidelines have explicitly been recommending clozapine as first-line therapy in TRS. We aimed to assess whether clozapine use in Germany has increased in recent years and to examine regional variations. Using claims data covering about 20% of the German population (GePaRD), we calculated the yearly prescription prevalence and incidence of clozapine among individuals aged 0\u201364 years based on outpatient dispensations. For 2022, we also assessed regional variations in clozapine prescription prevalence at the district level (restricted to\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009202 districts with \u226520,000 individuals). From 2012 to 2022, the overall (age- and sex-standardized) prescription prevalence of clozapine continuously decreased by 16% (from 77.6 to 65.5 per 100,000). The relative decline was greatest in women aged 30\u201339 years (-51%) and in men aged 30\u201334 years (-57%), in urban areas (large urban cities: -23%; urban districts: -16%), and in regions with high socioeconomic status (-22%). Over the same period, the overall prescription incidence of clozapine decreased by 41%. In 2022, regional clozapine prescription prevalence differed up to 39-fold. In conclusion, clozapine prescribing in Germany did not increase from 2012 to 2022, despite new clozapine-favoring guidelines, and showed substantial regional variation. Our results suggest a persisting underutilization of clozapine in most of Germany. Further research on barriers and facilitators for clozapine use in Germany is needed.\n                  <\/jats:p>","DOI":"10.1038\/s41537-026-00763-w","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:35:02Z","timestamp":1778733302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clozapine prescribing in Germany: temporal trends and regional variations, 2012\u20132022"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-6587","authenticated-orcid":false,"given":"Oliver H. F.","family":"Scholle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-502X","authenticated-orcid":false,"given":"Oliver","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9291-5739","authenticated-orcid":false,"given":"Mishal","family":"Qubad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"D\u00f6rks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Kollhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2021-0358","authenticated-orcid":false,"given":"Robert A.","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7526-2660","authenticated-orcid":false,"given":"Christian J.","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"763_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/YCO.0000000000000871","volume":"36","author":"RA Bittner","year":"2023","unstructured":"Bittner, R. A., Reif, A. & Qubad, M. The ever-growing case for clozapine in the treatment of schizophrenia: an obligation for psychiatrists and psychiatry. Curr. Opin. Psychiatry 36, 327\u2013336 (2023).","journal-title":"Curr. Opin. Psychiatry"},{"key":"763_CR2","first-page":"448","volume":"45","author":"E Diniz","year":"2023","unstructured":"Diniz, E. et al. Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates. Braz. J. Psychiatry 45, 448\u2013458 (2023).","journal-title":"Braz. J. Psychiatry"},{"key":"763_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1192\/bjp.2021.61","volume":"220","author":"D Siskind","year":"2022","unstructured":"Siskind, D. et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br. J. Psychiatry 220, 115\u2013120 (2022).","journal-title":"Br. J. Psychiatry"},{"key":"763_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes, O. D. et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am. J. Psychiatry 174, 216\u2013229 (2017).","journal-title":"Am. J. Psychiatry"},{"key":"763_CR5","doi-asserted-by":"crossref","unstructured":"Kane, J. M. et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J. Clin. Psychiatry 80, 18com12123 (2019).","DOI":"10.4088\/JCP.18com12123"},{"key":"763_CR6","doi-asserted-by":"crossref","unstructured":"Qubad, M. & Bittner, R. A. Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia. Ther. Adv. Psychopharmacol. 13, 20451253231158152 (2023).","DOI":"10.1177\/20451253231158152"},{"key":"763_CR7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn, M. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394, 939\u2013951 (2019).","journal-title":"Lancet"},{"key":"763_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1192\/bjp.2022.1","volume":"220","author":"S Brodeur","year":"2022","unstructured":"Brodeur, S. et al. Association between previous and future antipsychotic adherence in patients initiating clozapine: real-world observational study. Br. J. Psychiatry 220, 347\u2013354 (2022).","journal-title":"Br. J. Psychiatry"},{"key":"763_CR9","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1001\/jamapsychiatry.2019.1702","volume":"76","author":"T Masuda","year":"2019","unstructured":"Masuda, T., Misawa, F., Takase, M., Kane, J. M. & Correll, C. U. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics. JAMA Psychiatry 76, 1052\u20131062 (2019).","journal-title":"JAMA Psychiatry"},{"key":"763_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/wps.20699","volume":"19","author":"H Taipale","year":"2020","unstructured":"Taipale, H. et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry 19, 61\u201368 (2020).","journal-title":"World Psychiatry"},{"key":"763_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/wps.20994","volume":"21","author":"CU Correll","year":"2022","unstructured":"Correll, C. U. et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry 21, 248\u2013271 (2022).","journal-title":"World Psychiatry"},{"key":"763_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.euroneuro.2022.12.011","volume":"69","author":"VG Masdrakis","year":"2023","unstructured":"Masdrakis, V. G. & Baldwin, D. S. Prevention of suicide by clozapine in mental disorders: systematic review. Eur. Neuropsychopharmacol. 69, 4\u201323 (2023).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"763_CR13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S2215-0366(25)00297-4","volume":"12","author":"JJ Luykx","year":"2025","unstructured":"Luykx, J. J. et al. Transdiagnostic effectiveness and safety of clozapine in individuals with psychotic, affective, and personality disorders: nationwide and meta-analytic comparisons with other antipsychotics. Lancet Psychiatry 12, 921\u2013931 (2025).","journal-title":"Lancet Psychiatry"},{"key":"763_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103291","volume":"84","author":"M Samara","year":"2025","unstructured":"Samara, M. et al. Efficacy and tolerability of pharmacological interventions for schizophrenia non-responsive to prior treatment: a systematic review and network meta-analysis. eClinicalMedicine 84, 103291 (2025).","journal-title":"eClinicalMedicine"},{"key":"763_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","volume":"158","author":"M Chakos","year":"2001","unstructured":"Chakos, M., Lieberman, J., Hoffman, E., Bradford, D. & Sheitman, B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 158, 518\u2013526 (2001).","journal-title":"Am. J. Psychiatry"},{"key":"763_CR16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane, J., Honigfeld, G., Singer, J. & Meltzer, H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45, 789\u2013796 (1988).","journal-title":"Arch. Gen. Psychiatry"},{"key":"763_CR17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41386-019-0577-3","volume":"45","author":"Y Mizuno","year":"2020","unstructured":"Mizuno, Y., McCutcheon, R. A., Brugger, S. P. & Howes, O. D. Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. Neuropsychopharmacology 45, 622\u2013631 (2020).","journal-title":"Neuropsychopharmacology"},{"key":"763_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01613-2","volume":"11","author":"E Wagner","year":"2021","unstructured":"Wagner, E. et al. Efficacy and safety of clozapine in psychotic disorders\u2014a systematic quantitative meta-review. Transl. Psychiatry 11, 487 (2021).","journal-title":"Transl. Psychiatry"},{"key":"763_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","volume":"60","author":"HY Meltzer","year":"2003","unstructured":"Meltzer, H. Y. et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60, 82\u201391 (2003).","journal-title":"Arch. Gen. Psychiatry"},{"key":"763_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","volume":"6","author":"HY Meltzer","year":"2012","unstructured":"Meltzer, H. Y. Clozapine: balancing safety with superior antipsychotic efficacy. Clin. Schizophr. Relat. Psychoses 6, 134\u2013144 (2012).","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"763_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.schres.2004.05.015","volume":"73","author":"J Hennen","year":"2005","unstructured":"Hennen, J. & Baldessarini, R. J. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr. Res. 73, 139\u2013145 (2005).","journal-title":"Schizophr. Res."},{"key":"763_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/026988110101500209","volume":"15","author":"SG Siris","year":"2001","unstructured":"Siris, S. G. Suicide and schizophrenia. J. Psychopharmacol. 15, 127\u2013135 (2001).","journal-title":"J. Psychopharmacol."},{"key":"763_CR23","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1017\/S146114571100201X","volume":"15","author":"C Frogley","year":"2012","unstructured":"Frogley, C., Taylor, D., Dickens, G. & Picchioni, M. A systematic review of the evidence of clozapine\u2019s anti-aggressive effects. Int. J. Neuropsychopharmacol. 15, 1351\u20131371 (2012).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"763_CR24","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1038\/s41386-018-0161-2","volume":"43","author":"MDM Faay","year":"2018","unstructured":"Faay, M. D. M., Czobor, P. & Sommer, I. E. C. Efficacy of typical and atypical antipsychotic medication on hostility in patients with psychosis-spectrum disorders: a review and meta-analysis. Neuropsychopharmacol 43, 2340\u20132349 (2018).","journal-title":"Neuropsychopharmacol"},{"key":"763_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/acps.13291","volume":"144","author":"M L\u00e4hteenvuo","year":"2021","unstructured":"L\u00e4hteenvuo, M. et al. Morbidity and mortality in schizophrenia with comorbid substance use disorders. Acta Psychiatr. Scand. 144, 42\u201349 (2021).","journal-title":"Acta Psychiatr. Scand."},{"key":"763_CR26","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1192\/bjp.2022.117","volume":"221","author":"M L\u00e4hteenvuo","year":"2022","unstructured":"L\u00e4hteenvuo, M. et al. Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts. Br. J. Psychiatry 221, 758\u2013765 (2022).","journal-title":"Br. J. Psychiatry"},{"key":"763_CR27","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/schbul\/sbl003","volume":"32","author":"MF Brunette","year":"2006","unstructured":"Brunette, M. F., Drake, R. E., Xie, H., McHugo, G. J. & Green, A. I. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr. Bull. 32, 637\u2013643 (2006).","journal-title":"Schizophr. Bull."},{"key":"763_CR28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S2215-0366(24)00366-3","volume":"12","author":"H Taipale","year":"2025","unstructured":"Taipale, H. et al. Comparative effectiveness of antipsychotic treatment strategies for relapse prevention in first-episode schizophrenia in Finland: a population-based cohort study. Lancet Psychiatry 12, 122\u2013130 (2025).","journal-title":"Lancet Psychiatry"},{"key":"763_CR29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/schbul\/sbab087","volume":"48","author":"M Solmi","year":"2021","unstructured":"Solmi, M. et al. Antipsychotics use is associated with greater adherence to cardiometabolic medications in patients with schizophrenia: results from a nationwide, within-subject design study. Schizophr. Bull. 48, 166\u2013175 (2021).","journal-title":"Schizophr. Bull."},{"key":"763_CR30","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/schbul\/sbaa060","volume":"46","author":"E Wagner","year":"2020","unstructured":"Wagner, E. et al. Clozapine combination and augmentation strategies in patients with schizophrenia\u2014recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophr. Bull. 46, 1459\u20131470 (2020).","journal-title":"Schizophr. Bull."},{"key":"763_CR31","doi-asserted-by":"crossref","unstructured":"Jones, R. et al. Duration of prior psychotic illness and clozapine response: a retrospective observational study using electronic health records. Ther. Adv. Psychopharmacol. 12, 20451253221103353 (2022).","DOI":"10.1177\/20451253221103353"},{"key":"763_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00406-019-01053-6","volume":"270","author":"P Shah","year":"2020","unstructured":"Shah, P. et al. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. Eur. Arch. Psychiatry Clin. Neurosci. 270, 11\u201322 (2020).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"763_CR33","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.schres.2015.07.045","volume":"168","author":"Y Yada","year":"2015","unstructured":"Yada, Y., Yoshimura, B. & Kishi, Y. Correlation between delay in initiating clozapine and symptomatic improvement. Schizophr. Res. 168, 585\u2013586 (2015).","journal-title":"Schizophr. Res."},{"key":"763_CR34","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S2215-0366(25)00031-8","volume":"12","author":"RA McCutcheon","year":"2025","unstructured":"McCutcheon, R. A. et al. INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia. Lancet Psychiatry 12, 384\u2013394 (2025).","journal-title":"Lancet Psychiatry"},{"key":"763_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41537-021-00192-x","volume":"8","author":"CU Correll","year":"2022","unstructured":"Correll, C. U. et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia 8, 5 (2022).","journal-title":"Schizophrenia"},{"key":"763_CR36","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde. S3-Leitlinie Schizophrenie \u2013 Living Guideline (AWMF Registry No. 038-009; Version 4.0). Association of the Scientific Medical Societies in Germany (AWMF). https:\/\/register.awmf.org\/de\/leitlinien\/detail\/038-009 (2025)."},{"key":"763_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/acps.12742","volume":"136","author":"CJ Bachmann","year":"2017","unstructured":"Bachmann, C. J. et al. International trends in clozapine use: a study in 17 countries. Acta Psychiat Scand 136, 37\u201351 (2017).","journal-title":"Acta Psychiat Scand"},{"key":"763_CR38","doi-asserted-by":"publisher","unstructured":"Haug, U. & Schink, T. German Pharmacoepidemiological Research Database (GePaRD). in Databases for Pharmacoepidemiological Research (eds. Sturkenboom, M. & Schink, T.) 119\u2013124 (Springer, https:\/\/doi.org\/10.1007\/978-3-030-51455-6_8. 2021)","DOI":"10.1007\/978-3-030-51455-6_8"},{"key":"763_CR39","unstructured":"Bau-, B. f\u00fcr & Stadt- und Raumforschung (BBSR). Siedlungsstruktureller Kreistyp. https:\/\/www.bbsr.bund.de\/BBSR\/DE\/forschung\/raumbeobachtung\/Raumabgrenzungen\/deutschland\/kreise\/siedlungsstrukturelle-kreistypen\/kreistypen.html (2026)."},{"key":"763_CR40","doi-asserted-by":"publisher","unstructured":"Michalski, N., Reis, M., Tetzlaff, F., Nowossadeck, E. & Hoebel, J. German Index of Socioeconomic Deprivation (GISD), Berlin: Zenodo. https:\/\/doi.org\/10.5281\/zenodo.7973846 (2022).","DOI":"10.5281\/zenodo.7973846"},{"key":"763_CR41","unstructured":"BBSR. Indikatoren und Karten zur Raum- und Stadtentwicklung. INKAR. Ausgabe 2024. Hrsg.Bundesinstitut f\u00fcr Bau-, Stadt- und Raumforschung (BBSR) im Bundesamt f\u00fcr Bauwesen und Raumordnung (BBR), Bonn. https:\/\/www.inkar.de (2024)."},{"key":"763_CR42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41537-025-00689-9","volume":"11","author":"O Riedel","year":"2025","unstructured":"Riedel, O. et al. Prevalence and incidence of treated schizophrenia: temporal and regional trends in Germany. Schizophrenia 11, 131 (2025).","journal-title":"Schizophrenia"},{"key":"763_CR43","doi-asserted-by":"publisher","unstructured":"Seifert, J., Bleich, S. & Seifert, R. Depression, Angstst\u00f6rungen, bipolare St\u00f6rung, Schizophrenie, Aufmerksamkeitsdefizit-\/Hyperaktivit\u00e4tsst\u00f6rung. in Arzneiverordnungs-Report 2024 (eds. Ludwig, W.-D., M\u00fchlbauer, B. & Seifert, R.) 485\u2013535 (Springer, Berlin, Heidelberg, https:\/\/doi.org\/10.1007\/978-3-662-70594-0_22. 2025).","DOI":"10.1007\/978-3-662-70594-0_22"},{"key":"763_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","volume":"30","author":"J McGrath","year":"2008","unstructured":"McGrath, J., Saha, S., Chant, D. & Welham, J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Rev. 30, 67\u201376 (2008).","journal-title":"Epidemiologic Rev."},{"key":"763_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-015-0578-7","volume":"15","author":"JC Simeone","year":"2015","unstructured":"Simeone, J. C., Ward, A. J., Rotella, P., Collins, J. & Windisch, R. An evaluation of variation in published estimates of schizophrenia prevalence from 1990\u25002013: a systematic literature review. BMC Psychiatry 15, 193 (2015).","journal-title":"BMC Psychiatry"},{"key":"763_CR46","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1055\/s-0031-1275711","volume":"74","author":"F Hoffmann","year":"2012","unstructured":"Hoffmann, F. & Icks, A. Structural differences between health insurance funds and their impact on health services research: results from the Bertelsmann Health-Care Monitor. Gesundheitswesen 74, 291\u2013297 (2012).","journal-title":"Gesundheitswesen"},{"key":"763_CR47","doi-asserted-by":"publisher","unstructured":"Rothman, K. J. & Greenland, S. Basic concepts. in Handbook of Epidemiology (eds. Ahrens, W. & Pigeot, I.) (Springer, https:\/\/doi.org\/10.1007\/978-1-4614-6625-3_44-1. 2023).","DOI":"10.1007\/978-1-4614-6625-3_44-1"},{"key":"763_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2217-1","volume":"19","author":"C-L Hou","year":"2019","unstructured":"Hou, C.-L. et al. Psychotropic medication treatment patterns in community-dwelling schizophrenia in China: comparisons between rural and urban areas. BMC Psychiatry 19, 242 (2019).","journal-title":"BMC Psychiatry"},{"key":"763_CR49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1192\/pb.bp.112.042143","volume":"38","author":"DJ Martin","year":"2014","unstructured":"Martin, D. J. et al. Socioeconomic status and prescribing for schizophrenia: analysis of 3200 cases from the Glasgow Psychosis Clinical Information System (PsyCIS). Psychiatr. Bull. 38, 54\u201357 (2014).","journal-title":"Psychiatr. Bull."},{"key":"763_CR50","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/schbul\/sbs096","volume":"38","author":"E Vassos","year":"2012","unstructured":"Vassos, E., Pedersen, C. B., Murray, R. M., Collier, D. A. & Lewis, C. M. Meta-analysis of the association of urbanicity with schizophrenia. Schizophr. Bull. 38, 1118\u20131123 (2012).","journal-title":"Schizophr. Bull."},{"key":"763_CR51","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/schbul\/sbm032","volume":"33","author":"S Werner","year":"2007","unstructured":"Werner, S., Malaspina, D. & Rabinowitz, J. Socioeconomic status at birth is associated with risk of schizophrenia: population-based multilevel study. Schizophr. Bull. 33, 1373\u20131378 (2007).","journal-title":"Schizophr. Bull."},{"key":"763_CR52","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamapsychiatry.2015.0346","volume":"72","author":"E Agerbo","year":"2015","unstructured":"Agerbo, E. et al. Polygenic risk score, parental socioeconomic status, family history of psychiatric disorders, and the risk for schizophrenia: a Danish population-based study and meta-analysis. JAMA Psychiatry 72, 635\u2013641 (2015).","journal-title":"JAMA Psychiatry"},{"key":"763_CR53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1017\/S0033291719002083","volume":"51","author":"SE Smart","year":"2021","unstructured":"Smart, S. E., K\u0119pi\u0144ska, A. P., Murray, R. M. & MacCabe, J. H. Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies. Psychol. Med. 51, 44\u201353 (2021).","journal-title":"Psychol. Med."},{"key":"763_CR54","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S2215-0366(15)00575-1","volume":"3","author":"T Wimberley","year":"2016","unstructured":"Wimberley, T. et al. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry 3, 358\u2013366 (2016).","journal-title":"Lancet Psychiatry"},{"key":"763_CR55","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.schres.2023.03.010","volume":"255","author":"RA Benito","year":"2023","unstructured":"Benito, R. A. et al. Thirteen-fold variation between states in clozapine prescriptions to United States Medicaid patients. Schizophr. Res. 255, 79\u201381 (2023).","journal-title":"Schizophr. Res."},{"key":"763_CR56","doi-asserted-by":"publisher","first-page":"e0328495","DOI":"10.1371\/journal.pone.0328495","volume":"20","author":"LR Cavanah","year":"2025","unstructured":"Cavanah, L. R., Tian, M. Y., Goldhirsh, J. L., Huey, L. Y. & Piper, B. J. Declines and pronounced state-level variation in clozapine use among Medicare patients. PLoS ONE 20, e0328495 (2025).","journal-title":"PLoS ONE"},{"key":"763_CR57","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/acps.13280","volume":"143","author":"E Whiskey","year":"2021","unstructured":"Whiskey, E. et al. An evaluation of the variation and underuse of clozapine in the United Kingdom. Acta Psychiatr. Scand. 143, 339\u2013347 (2021).","journal-title":"Acta Psychiatr. Scand."},{"key":"763_CR58","first-page":"3","volume":"124","author":"S Higuchi","year":"2022","unstructured":"Higuchi, S. et al. Clozapine use in Japan based on national database of health insurance claims and specific health checkups open data: disparities by region, age, and sex. Psychiatr. Neurol. Jpn. 124, 3\u201315 (2022).","journal-title":"Psychiatr. Neurol. Jpn."},{"key":"763_CR59","doi-asserted-by":"crossref","unstructured":"Schou, M. B., Drange, O. K. & S\u00e6ther, S. G. Fylkesvise forskjeller i forskrivning av klozapin. Tidsskr. Den Nor. legeforening 139, (2019).","DOI":"10.4045\/tidsskr.19.0151"},{"key":"763_CR60","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.chb.2019.07.028","volume":"101","author":"AN Saiphoo","year":"2019","unstructured":"Saiphoo, A. N. & Vahedi, Z. A meta-analytic review of the relationship between social media use and body image disturbance. Comput. Hum. Behav. 101, 259\u2013275 (2019).","journal-title":"Comput. Hum. Behav."},{"key":"763_CR61","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41537-025-00570-9","volume":"11","author":"MZ van derHorst","year":"2025","unstructured":"van derHorst, M. Z. et al. Determinants of patient satisfaction in clozapine users: results from the Clozapine International Consortium (CLOZIN). Schizophrenia 11, 28 (2025).","journal-title":"Schizophrenia"},{"key":"763_CR62","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/acps.12294","volume":"130","author":"D Cohen","year":"2014","unstructured":"Cohen, D. Prescribers fear as a major side-effect of clozapine. Acta Psychiatr. Scand. 130, 154\u2013155 (2014).","journal-title":"Acta Psychiatr. Scand."},{"key":"763_CR63","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10597-021-00847-0","volume":"58","author":"RO Cotes","year":"2022","unstructured":"Cotes, R. O. et al. A comparison of attitudes, comfort, and knowledge of clozapine among two diverse samples of US psychiatrists. Community Ment. Heal. J. 58, 517\u2013525 (2022).","journal-title":"Community Ment. Heal. J."},{"key":"763_CR64","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.euroneuro.2024.04.012","volume":"84","author":"O Agid","year":"2024","unstructured":"Agid, O. et al. Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: a narrative review and recommendation for clinical practice. Eur. Neuropsychopharmacol. 84, 35\u201347 (2024).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"763_CR65","doi-asserted-by":"crossref","unstructured":"Qubad, M., Ehret, I. M., Bachmann, C. J. & Bittner, R. A. Adult psychiatrists\u2019 views on clozapine prescribing for schizophrenia in Germany \u2013 an online survey. Ther. Adv. Psychopharmacol. 16, 20451253261434380 (2026).","DOI":"10.1177\/20451253261434380"},{"key":"763_CR66","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1177\/0706743718772522","volume":"63","author":"AP John","year":"2018","unstructured":"John, A. P., Ko, E. K. F. & Dominic, A. Delayed initiation of clozapine continues to be a substantial clinical concern. Can. J. Psychiatry 63, 526\u2013531 (2018).","journal-title":"Can. J. Psychiatry"},{"key":"763_CR67","doi-asserted-by":"crossref","unstructured":"Rubio, J. M. & Kane, J. M. How to make an effective offer of clozapine. J. Clin. Psychiatry 83, 21ac14000 (2021).","DOI":"10.4088\/JCP.21ac14000"},{"key":"763_CR68","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1600-0447.2011.01711.x","volume":"123","author":"JM Kane","year":"2011","unstructured":"Kane, J. M. A user\u2019s guide to clozapine. Acta Psychiatr. Scand. 123, 407\u2013408 (2011).","journal-title":"Acta Psychiatr. Scand."},{"key":"763_CR69","doi-asserted-by":"publisher","first-page":"sgac042","DOI":"10.1093\/schizbullopen\/sgac042","volume":"3","author":"S Parkes","year":"2022","unstructured":"Parkes, S., Mantell, B., Oloyede, E. & Blackman, G. Patients\u2019 experiences of clozapine for treatment-resistant schizophrenia: a systematic review. Schizophr. Bull. Open 3, sgac042 (2022).","journal-title":"Schizophr. Bull. Open"},{"key":"763_CR70","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/schbul\/sbac014","volume":"48","author":"J Lieslehto","year":"2022","unstructured":"Lieslehto, J., Tiihonen, J., L\u00e4hteenvuo, M., Tanskanen, A. & Taipale, H. Primary nonadherence to antipsychotic treatment among persons with schizophrenia. Schizophr. Bull. 48, 655\u2013663 (2022).","journal-title":"Schizophr. Bull."},{"key":"763_CR71","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1600-0447.2012.01863.x","volume":"126","author":"PR Falzer","year":"2012","unstructured":"Falzer, P. R. & Garman, D. M. Optimizing clozapine through clinical decision making. Acta Psychiatr. Scand. 126, 47\u201358 (2012).","journal-title":"Acta Psychiatr. Scand."},{"key":"763_CR72","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S2215-0366(25)00098-7","volume":"13","author":"D Siskind","year":"2026","unstructured":"Siskind, D. et al. Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: consensus guidelines from a global Delphi panel. Lancet Psychiatry 13, 77\u201386 (2026).","journal-title":"Lancet Psychiatry"},{"key":"763_CR73","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/17512433.2023.2183192","volume":"16","author":"JG Leung","year":"2023","unstructured":"Leung, J. G., Ehret, M., Love, R. C. & Cotes, R. O. Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issues. Expert Rev. Clin. Pharmacol. 16, 177\u2013179 (2023).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"763_CR74","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1192\/j.eurpsy.2020.110","volume":"64","author":"D Cohen","year":"2020","unstructured":"Cohen, D. & Farooq, S. Mandatory certification for clozapine prescribing. Eur. Psychiatry 64, e12 (2020).","journal-title":"Eur. Psychiatry"},{"key":"763_CR75","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/acps.12327","volume":"130","author":"K Beck","year":"2014","unstructured":"Beck, K. et al. The practical management of refractory schizophrenia \u2013 the Maudsley Treatment REview and Assessment Team service approach. Acta Psychiatr. Scand. 130, 427\u2013438 (2014).","journal-title":"Acta Psychiatr. Scand."},{"key":"763_CR76","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2026.10988","volume":"12","author":"ZA Khan","year":"2026","unstructured":"Khan, Z. A. et al. Treating Unmet Needs in Psychiatry (TUNE-UP): targeted service increases out-patient initiations of clozapine. BJPsych Open 12, e73 (2026).","journal-title":"BJPsych Open"},{"key":"763_CR77","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2024.1816","volume":"68","author":"H Verdoux","year":"2025","unstructured":"Verdoux, H. et al. The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force. Eur. Psychiatry 68, e17 (2025).","journal-title":"Eur. Psychiatry"},{"key":"763_CR78","doi-asserted-by":"crossref","unstructured":"Meyer, J. M. & Rubio, J. M. Clozapine Monitoring in the Post-REMS World. J. Clin. Psychiatry 86, 25ac15898 (2025).","DOI":"10.4088\/JCP.25ac15898"},{"key":"763_CR79","doi-asserted-by":"crossref","unstructured":"Diederich, F., Oloyede, E., Taylor, D. & Bachmann, C. J. Economic evaluation of different haematological monitoring schemes for patients with treatment-resistant schizophrenia using clozapine. Br. J. Psychiatry 13, 1\u20138 (2025).","DOI":"10.1192\/bjp.2025.10424"}],"container-title":["Schizophrenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41537-026-00763-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-026-00763-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-026-00763-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:02:24Z","timestamp":1778738544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41537-026-00763-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1038\/s41537-026-00763-w","relation":{},"ISSN":["2754-6993"],"issn-type":[{"value":"2754-6993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.H.F.S., O.R., and B.K. are working at an independent, non-profit research institute, the Leibniz Institute for Prevention Research and Epidemiology\u2014BIPS. Unrelated to this study, BIPS occasionally conducts studies financed by the pharmaceutical industry. These are post-authorization safety studies (PASS) requested by health authorities. The design and conduct of these studies, as well as the interpretation and publication are not influenced by the pharmaceutical industry. The study presented was not funded by the pharmaceutical industry. M.D. declares no conflict of interest. M.Q., R.A.B., and C.J.B. are members of the European Clozapine Task Force, an informal association of European clinicians with an interest in improving access to clozapine for patients with schizophrenia. M.Q. received speaker fees from Recordati Pharma GmbH and Otsuka Pharma GmbH. R.A.B. has received advisory board fees from Newron and has received speaker fees from Recordati Pharma GmbH.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}